Riskpilot← Back to searchSign inGet full accessNipoptik Sollefteå AB
ABActiveOrg 5560611112Centrumplan 7Retail sale of medical and orthopaedic goods · NACE 4774Est. 19551-4 employees
Revenue 2025
SEK 8,5M
-2% vs 2024
EBITDA margin
20.5%
+25% vs 2024
Equity ratio
31.7%
Financial strength
Net profit 2025
SEK 1,7M
+63% vs 2024
| Revenue | SEK 8,5M | -2% |
| EBITDA | SEK 1,7M | +25% |
| Net profit | SEK 1,7M | +63% |
| Total assets | SEK 9,7M | +19% |
| Equity | SEK 3,1M | +31% |
| Employees | — | — |
Legal name
Nipoptik Sollefteå AB
Org number
5560611112
Legal form
Aktiebolag
NACE code
4774 · Retail sale of medical and orthopaedic goods
Founded
1 april 1955
Share capital
SEK 100 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av suppleanten Styrelsen ska bestå av 1 styrelseledamot och 1 styrelsesuppleant.
Company purpose
Bolagets verksamhet ska vara att bedriva handel med ur, optik, utföra synvårdsundersökningar samt därmed förenlig verksamhet.
Address
Centrumplan 7
Phone
+4662017575
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 8 195 | 8 448 | 8 466 | 8 704 | 8 541 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 1 028 | 1 644 | 1 109 | 1 401 | 1 747 |
| Depreciation & amort. | −19 | −13 | −23 | −29 | −29 |
| EBIT | 1 009 | 1 631 | 1 086 | 1 372 | 1 718 |
| Net financials | −1 | −3 | 5 | 128 | 68 |
| Profit before tax | 968 | 1 232 | 976 | 1 375 | 2 214 |
| Tax | −224 | −251 | −224 | −312 | −481 |
| Net profit | 744 | 981 | 752 | 1 063 | 1 733 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 7 378 | 8 043 | 8 174 | 8 155 | 9 709 |
| Equity | 2 957 | 2 437 | 2 030 | 2 343 | 3 076 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 544 | 3 331 | 3 755 | 3 344 | 4 612 |
| Total debt | 2 544 | 3 331 | 3 755 | 3 344 | 4 612 |
EBITDA margin
20.5%
This company
15.8%
Market median
+30% vs market
20212025
Equity ratio
31.7%
This company
38.2%
Market median
+17% vs market
20212025
Return on equity
56.3%
This company
18.4%
Market median
+206% vs market
20212025
Net profit margin
20.3%
This company
8.1%
Market median
+151% vs market
20212025
Asset turnover
0.88×
This company
1.12×
Market median
+21% vs market
20212025
Debt / equity
2.16×
This company
0.62×
Market median
-248% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LM | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Board of Directors | 2022 – 2026 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Nipoptik AB
Nipoptik Sollefteå AB Board members of Nipoptik Sollefteå AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lena Marie Gabrielsson | Audit | 0 companies |
| Sara Pernilla Drömer | Deputy Board Member | 0 companies |
| Bengt Johan Pontus Drömer | Board of Directors | 0 companies |